Galapagos NV: business update: http://t.co/6w1jppWE
posted 6 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that, as the result of the exercise of warrants by a number of the Company’s employees and the private placement announced on 28 March 2012, ThromboGenics now has a total of 35,691,432 shares outstanding and listed on NYSE Euronext Brussels. read more
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces the launch of a private placement of new ordinary shares to raise up to 10% of the current number of outstanding shares (i.e. 3,244,675 new shares). The Board of Directors has resolved to disapply the preferential subscription rights of existing shareholders in connection with the intended capital increase, which will take place within the limits of the authorized share capital in accordance with article 604 of the Belgian Company Code. read more
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for Q4 and full year 2011. read more
Merger completed successfully - ChondroCelect® commercial roll-out progressing - clinical programs on track - substantial non-dilutive funding - EUR 20 million cash at 31 Dec. 2011 read more
Devgen nv (Euronext Brussels: DEVG), an agro-biotech company developing and commercializing hybrid seeds and crop protection solutions, today provides a business update and its results for the twelve month period ending 31st December 2011. During this period, Devgen has reached a key milestone in the development of its Next Generation Hybrid Rice seeds (NGHRTM), broadened its current offering of hybrid seeds, improved its market access and strengthened its balance sheet. Devgen believes the company is well placed to deliver on its goal of shaping the field of hybrid rice in India and Southeast Asia, thus helping farmers meet the productivity increases needed to grow more food on less land using less water, labor and agrochemicals. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued a business update and its financial results for the full year ending December 31, 2011. read more
Galapagos NV (Euronext: GLPG) announced today that it has received a transparency notification pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007) concerning major holdings in Belgian listed companies from Abingworth Management Limited. read more
